Britain Is Finally Ready to Authorize CBD Foods. Europe Could Rewrite the Rules Again

For years, Britain’s CBD sector has occupied a peculiar regulatory middle ground. Thousands of products have remained on shelves while technically classified as unauthorized novel foods, tolerated under an interim system as regulators worked through a backlog of applications.

That may finally be about to change.

The UK Food Standards Agency is preparing to recommend the country’s first market authorizations for CBD foods, beginning with three applications connected to Pureis CBD, Cannaray and a consortium organized by the European Industrial Hemp Association.

If ministers approve the recommendations, approximately 3,000 products linked to those applications could begin moving from provisional status toward full regulatory compliance.

But the breakthrough arrives with an expiration date hanging over it. Britain is negotiating a sanitary and phytosanitary agreement with the European Union that could eventually replace domestic CBD approvals with the EU’s considerably more restrictive system.

The result is an unusual regulatory moment: Britain is preparing to establish its first legal pathway for CBD foods just as negotiations with Brussels could force it to surrender that pathway.

Three Applications, Thousands of Products

The FSA paper published September 3 covers the first three high-purity CBD applications to complete safety assessment and public consultation:

• RP 7: Synthetic CBD associated with Chanelle McCoy CBD Ltd. and its Pureis brand.
• RP 350: A CBD isolate application from Cannaray Brands Ltd.
• RP 427: A hemp-derived CBD isolate submitted by EIHA Projects GmbH on behalf of participating companies.

All three ingredients contain at least 98% CBD and are intended for adults at a maximum intake of 10 milligrams per day. The FSA and Food Standards Scotland concluded that each was safe under its proposed conditions of use, based on advice from the Advisory Committee on Novel Foods and Processes.

This does not mean the products have already been authorized.

The FSA board is being asked to endorse the agency’s risk-management recommendations and allow officials to submit them to ministers in England and Wales. Ministers will make the final decisions about authorization and the conditions attached to it. Scotland is conducting its own process through Food Standards Scotland.

Nevertheless, the recommendations represent what the agency called a “major milestone” for the CBD sector. If approved, they would produce the first CBD novel-food authorizations in Great Britain.

The immediate commercial effect could extend far beyond three ingredients. Approximately 3,000 individual products on the FSA’s CBD Public List are linked to these applications.

That list was introduced in England and Wales as an interim mechanism for managing a market that already existed while applications moved through the novel-food process. Regulators have advised local authorities to prioritize enforcement against products that do not appear on the list.

Inclusion, however, has never amounted to legal authorization. The products remain unauthorized novel foods, and local authorities retain responsibility for enforcement.

Ministerial approval would begin closing that gap.

What Companies Would Be Allowed to Sell

The proposed authorizations are narrow and application-specific.

All three applications cover food supplements. RP 350 would also be permitted in certain beverages and confectionery products because those additional categories were requested and assessed in the application.

RP 427 is more limited. It covers hemp-derived CBD isolate dissolved in hemp-seed oil and sold in adult food supplements such as capsules, liquids or drops. Incorporating that ingredient into other foods would not automatically be permitted.

That distinction matters because novel-food authorization applies to the specific ingredient, manufacturing specifications and conditions of use examined by regulators. It is not a blanket approval for companies to place CBD into any product they choose.

Authorized products would also need to comply with Britain’s existing food-supplement regulations and strict specifications governing delta-9 THC and other controlled cannabinoids.

For RP 427, the FSA adjusted its proposed delta-9 THC specification after the applicant supplied additional evidence during consultation. The new limit would allow a higher THC level than originally proposed because regulators concluded it was more consistently achievable and verifiable across production.

The agency said the revision remains consistent with the principle that contaminants should be kept “as low as reasonably achievable,” while producing a standard that manufacturers can meet and authorities can enforce.

The FSA is developing additional guidance for local authorities addressing cannabinoid controls and the intersection between food and drug legislation. That guidance is expected in the coming months.

The 10-Milligram Ceiling

The central condition is a provisional acceptable daily intake of 10 milligrams of CBD for a healthy 70-kilogram adult.

Products would need to display that limit and carry warnings advising against consumption by people under 18; those who are pregnant, breastfeeding or trying to conceive; people taking medication; and immunosuppressed consumers.

The agency revised its proposed language after respondents expressed concern that the original warning was too long and difficult to understand. The final wording is intended to make the daily limit clearer while retaining the warnings for vulnerable groups.

The ceiling applies to total daily consumption, not necessarily each individual product. A consumer taking a 10-milligram serving from one product would already have reached the provisional daily limit and should avoid consuming another CBD product that day.

The FSA’s safety work focused on potential adverse effects rather than therapeutic benefits. Its provisional intake was designed to protect against the most sensitive effects identified in the evidence, particularly effects involving the liver and thyroid, while accounting for gaps in long-term human data.

That creates an awkward issue around the products’ classification as food supplements.

Under Britain’s Food Supplements Regulations, a supplement is generally expected to provide a nutritional or physiological effect. The FSA said it has not seen evidence establishing such an effect at the proposed 10-milligram dose.

Consumers nevertheless routinely buy CBD in supplement formats. Agency research found that people reported using it for pain, anxiety, relaxation, sleep, mental health, depression, arthritis and back pain. Approximately two-thirds believed CBD had improved their health or helped with a medical condition, while more than one-third said they relied on it or would be bothered if it became unavailable.

Those reports reflect consumer perceptions, not clinical proof. The research did not establish how much CBD people consumed, how regularly they used it or whether their behavior matched the FSA’s recommended limit.

The agency nevertheless concluded that authorizing CBD in the supplement category was reasonable because consumers already recognize the products that way. Rejecting that category could disrupt the market and affect consumers who believe they depend on the products.

Authorization would not validate those perceived benefits. Existing prohibitions against unapproved health and medicinal claims would remain in force, and there are currently no authorized nutrition or health claims for CBD products in Great Britain.

In other words, companies may be allowed to sell an authorized CBD supplement—but not tell customers it treats pain, anxiety or insomnia.

Most Respondents Supported the Plan

The FSA ran a 12-week consultation beginning August 28, 2025, receiving 46 responses from consumers, applicants, trade groups, businesses and local authorities.

Sixty-eight percent supported the proposed risk-management approach.

Respondents generally accepted the need for daily intake information, warning labels and controlled-cannabinoid limits, although they requested clearer explanations and more workable requirements. The FSA said the feedback led to targeted changes rather than a fundamental revision of its approach.

The agency’s guiding principles remain consumer safety, proportionality, compliance, effective enforcement and public trust.

The three applicants have also requested protection for proprietary evidence used in their safety dossiers. If regulators determine that the statutory requirements are met, each applicant could receive five years of exclusivity for its authorized novel food.

During that period, another company could not rely on the protected evidence to obtain authorization without the applicant’s agreement. A competitor could still secure approval by producing an independent dossier that did not reference the protected data.

That provision could give the first successful applicants a meaningful commercial advantage after years of investment in toxicology studies and regulatory submissions.

They are unlikely to be alone for long. The FSA has already published 14 positive safety assessments covering CBD novel foods with purity above 97%. Future applications will be evaluated individually, although regulators may apply precedents established through these first authorizations when supported by the evidence.

Britain and Europe Disagree Over the Safe Dose

The largest unresolved issue sits outside the applications themselves.

Britain’s proposed 10-milligram daily limit is five times the provisional level established by the European Food Safety Authority.

In February 2026, EFSA set a provisional safe intake of 0.0275 milligrams per kilogram of body weight—approximately 2 milligrams per day for a 70-kilogram adult.

EFSA’s threshold applies only to food supplements containing CBD of at least 98% purity, without nanoparticles, when the production process is considered safe and genotoxicity has been excluded.

The European authority also concluded that CBD’s safety has not been established for people under 25, those who are pregnant or breastfeeding and people taking medication.

The FSA said the European and British calculations relied on different datasets, although both examined similar adverse effects and gaps in the safety evidence. It remains confident in its own 10-milligram provisional limit.

A second European development adds another layer of uncertainty. In March, the European Chemicals Agency’s Risk Assessment Committee recommended classifying CBD as a Category 1B reproductive and lactation toxicant, meaning it may damage fertility or an unborn child and may harm breastfed children.

That recommendation still requires a European Commission decision and does not itself determine whether CBD foods can be authorized.

The FSA previously reviewed the evidence underpinning the classification proposal and concluded that it did not contain new information requiring Britain to revise its 10-milligram limit. The agency continues to advise people who are pregnant, breastfeeding or trying to conceive not to consume CBD.

The Brexit Question Returns

Britain’s proposed authorizations may ultimately collide with its effort to negotiate a new sanitary and phytosanitary agreement with the EU.

The model under discussion involves dynamic alignment with European food rules. Unless the UK negotiates a specific exception, companies would eventually stop applying to the FSA and Food Standards Scotland for novel-food authorization and instead use the EU process.

EU authorizations would then cover the entire United Kingdom, while domestic authorizations issued in Great Britain would cease to apply.

That could expose companies to a stricter 2-milligram European safety threshold and a regulatory system in which EFSA has not yet issued a positive safety assessment for any CBD novel food.

The implications differ across the four UK nations.

The FSA will advise ministers in England and Wales, while Food Standards Scotland will advise Scottish ministers. Both agencies say they are working toward a consistent Great Britain-wide approach, with an existing common framework available to manage any divergence.

Northern Ireland operates differently under the Windsor Framework. Companies generally must apply through the EU system to place regulated products directly on the Northern Irish market. However, CBD foods authorized in Great Britain may potentially be moved into Northern Ireland as retail goods through the Northern Ireland Retail Movement Scheme, provided they qualify.

For CBD companies, the outcome of the SPS negotiations may therefore be as important as the ministerial decisions themselves.

The Bottom Line

These three applications would not legalize every CBD product in Britain, validate the industry’s health claims or end the novel-food backlog.

They would do something more foundational: establish the first functioning route from Britain’s provisional CBD market to full authorization.

Pureis, Cannaray and the EIHA consortium could receive five years of protection for proprietary safety data. Roughly 3,000 linked products could move closer to formal compliance. Other applicants would gain precedents for labeling, dosage, controlled cannabinoids and enforcement.

But companies still face a 10-milligram daily ceiling, strict warnings, narrow product permissions and no right to make health claims. They must also prepare for the possibility that a future UK-EU agreement replaces Britain’s domestic system with a European regime built around a 2-milligram threshold.

Britain is finally preparing to open the door to authorized CBD foods.